Patents Examined by Francesca Edgingtongiordan
-
Patent number: 11952410Abstract: The present disclosure provides constructs that comprise (a) a TNF-related apoptosis-inducing ligand (TRAIL) trimer comprising three consecutive extracellular TRAIL domains fused together in a head-to-tail configuration; (b) an epitope binding agent, and (c) optionally one or more additional components, wherein the epitope binding agent competitively inhibits binding of P4-TR3 or HN1-TR3 to cell surface human mesothelin. Constructs of the present disclosure induce apoptosis in cells expressing human mesothelin and a death receptor (DR4 or DR5) on the cell's surface.Type: GrantFiled: May 2, 2018Date of Patent: April 9, 2024Assignee: Washington UniversityInventors: Dirk M. Spitzer, William G. Hawkins
-
Patent number: 11945864Abstract: A monoclonal antibody or an antigen-binding fragment thereof according to an embodiment of the present invention can bind to lymphocyte-activation gene 3 (LAG-3) including a heavy chain variable region and a light chain variable region and inhibit the activity thereof. Thus it is expected to be useful for the development of immunotherapeutic agents for various disorders that are associated with LAG-3.Type: GrantFiled: June 28, 2019Date of Patent: April 2, 2024Assignee: Y-BIOLOGICS INC.Inventors: Sang Pil Lee, Ji-Young Shin, Sunha Yoon, Yunseon Choi, Jae Eun Park, Ji Su Lee, Youngja Song, Gisun Baek, Seok Ho Yoo, Yeung-chul Kim, Dong Jung Lee, Bum-Chan Park, Young Woo Park
-
Patent number: 11945851Abstract: Disclosed herein are compositions and methods for treating and/or preventing cancer in mammals, and in particular, vaccines that treat and provide protection against tumor growth.Type: GrantFiled: June 7, 2018Date of Patent: April 2, 2024Assignee: The Wistar Institute of Anatomy and BiologyInventors: David Weiner, Elizabeth Duperret
-
Patent number: 11919960Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in 5 pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: March 5, 2024Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
-
Patent number: 11912771Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.Type: GrantFiled: March 9, 2022Date of Patent: February 27, 2024Assignee: CDR-LIFE AGInventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner
-
Patent number: 11891449Abstract: The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.Type: GrantFiled: December 6, 2021Date of Patent: February 6, 2024Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.Inventors: Wenzhi Tian, Song Li, Dianze Chen
-
Patent number: 11884729Abstract: The present disclosure provides antibodies that specifically bind to L1CAM and compositions comprising such antibodies. Also provided herein are methods for preventing or treating diseases or conditions which comprise a tumor using the anti-L1CAM antibodies.Type: GrantFiled: June 27, 2019Date of Patent: January 30, 2024Assignee: ApitBio, IncInventors: Hyo Jeong Hong, Heesu Chae, Jisu Hong
-
Patent number: 11873341Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: January 16, 2024Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
-
Patent number: 11866492Abstract: A modified antibody that binds specifically to folate receptor alpha (FOLR1) and blocks the activity of FOLR1 with an increased binding affinity, an antigen-binding fragment thereof, a composition containing the antibody or fragment, and their uses are disclosed. The modified antibody or antigen-binding fragment thereof may be used for the prevention or treatment of cancer proliferative disorder associated with an increased FOR1 expression, and may also be used for diagnosis of the disease. The proliferative disorder may be cancer.Type: GrantFiled: March 13, 2019Date of Patent: January 9, 2024Assignee: ALTEOGEN, INC.Inventors: Soon Jae Park, Hye-Shin Chung, Sunbae Lee
-
Patent number: 11866500Abstract: Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.Type: GrantFiled: November 12, 2021Date of Patent: January 9, 2024Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Xing Sun, Guoqing Cao, Changyong Yang, Lianshan Zhang, Yong Guo
-
Patent number: 11851494Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: December 26, 2023Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
-
Patent number: 11834483Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).Type: GrantFiled: April 15, 2021Date of Patent: December 5, 2023Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Jared Lopes, Heather C. Losey, Raymond J. Winquist
-
Patent number: 11814434Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: November 14, 2023Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
-
Patent number: 11802161Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: October 31, 2023Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
-
Patent number: 11793867Abstract: Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.Type: GrantFiled: December 18, 2018Date of Patent: October 24, 2023Assignee: BIONTECH US INC.Inventor: Vikram Juneja
-
Patent number: 11779642Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.Type: GrantFiled: December 8, 2017Date of Patent: October 10, 2023Assignee: Alector LLCInventors: Andrew Pincetic, Arnon Rosenthal, Seung-Joo Lee